A new study, led by University of Oxford academics, found that medication rates for women over 25 surged from 0.01 per cent to 0.2 per cent by 2023, a more than 20-fold increase.
This dramatic increase among women is attributed to a growing understanding that ADHD often presents differently in females, frequently as inattentiveness rather than hyperactivity, leading to missed diagnoses in childhood.
Despite the rise in prescriptions, only 31 per cent of UK patients remained on their medication after one year, suggesting difficulties in finding suitable long-term treatment.
The study highlights that ADHD remains significantly undertreated compared to global prevalence estimates, with the NHS facing a crisis in neurodiversity services and long waiting lists for assessments.